Bispecific antibodies comprising a disulfide stabilized-Fv fragment

Patent metadata

Field	Value
Publication number	US-9879095-B2
Application number	US-201313773167-A
Country	US
Kind code	B2
Filing date	Feb 21, 2013
Priority date	Aug 24, 2010
Publication date	Jan 30, 2018
Grant date	Jan 30, 2018

Abstract

The present invention relates to bispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

First claim

What is claimed is:

1. A bispecific antibody comprising
a) a full length antibody specifically binding to a first antigen and consisting of two antibody heavy chains and two antibody light chains;
b) a Fv fragment specifically binding to a second antigen comprising a VH 2 domain and a VL 2 domain, wherein the VH 2 and VL 2 domains are connected via a disulfide bridge,
wherein only either the VH 2 domain or the VL 2 domain of the Fv fragment is fused via a peptide linker to the heavy or light chain of the full length antibody, and
wherein the Fv fragment is fused to the full length antibody via a single peptide linker.

2. The bispecific antibody according to claim 1 , wherein the bispecific antibody is trivalent and
either the VH 2 domain or the VL 2 domain of the Fv fragment is fused via a peptide linker to the heavy chain of the full length antibody.

3. The bispecific antibody according to claim 2 , wherein the VH 2 domain or the VL 2 domain of the Fv fragment is N-terminally fused via a peptide linker to the C-terminus of the full length antibody.

4. The bispecific antibody according to claim 2 , wherein the VH 2 domain or VL 2 domain of the Fv fragment is C-terminally fused via a peptide linker to the N-terminus of the full length antibody.

5. The bispecific antibody according to claim 1 , wherein the VH 2 domain or VL 2 domain of the Fv fragment is N-terminally fused via a peptide linker to the C-terminus of the heavy or light chain of the full length antibody.

6. The bispecific antibody according to claim 1 , wherein the VH 2 domain or VL 2 domain of the Fv fragment is C-terminally fused via a peptide linker to the N-terminus of the heavy or light chain of the full length antibody.

7. The bispecific antibody according to claim 1 , wherein the VH 2 domain and the VL 2 domain of the Fv fragment are connected via a disulfide bridge which is introduced between the following positions:
i) VH 2 domain position 44 and VL 2 domain position 100,
ii) VH 2 domain position 105 and VL 2 domain position 43, or
iii) VH 2 domain position 101 and VL 2 domain position 100,
wherein the numbering is according to Kabat.

8. The bispecific antibody according to claim 1 , wherein the VH 2 domain and the VL 2 domain of the Fv fragment are connected via a disulfide bridge which is introduced between the
VH 2 domain position 44 and VL 2 domain position 100,
wherein the numbering is according to Kabat.

9. The bispecific antibody according to claim 1 , wherein the full length antibody comprises a first CH3 domain and a second CH3 domain, and the first CH3 domain of the full length antibody and the second CH3 domain of the full length antibody each meet at an interface which comprises an alteration in the original interface between the first and second CH3 domains;
wherein i) in the first CH3 domain,
an amino acid residue is replaced with an amino acid residue having a larger side chain volume, thereby generating a protuberance within the interface of the first CH3 domain which is positionable in a cavity within the interface of the second CH3
and
ii) in the second CH3 domain,
an amino acid residue is replaced with an amino acid residue having a smaller side chain volume, thereby generating a cavity within the interface of the second CH3 domain within which a protuberance within the interface of the first CH3 domain is positionable.

10. The bispecific antibody according to claim 9 , wherein said amino acid residue having a larger side chain volume is selected from the group consisting of arginine (R), phenylalanine (F), tyrosine (Y), and tryptophan (W) and said amino acid residue having a smaller side chain volume is selected from the group consisting of alanine (A), serine (S), threonine (T), and valine (V).

11. The bispecific antibody according to claim 9 , wherein both the first and second CH3 domains are further altered by the introduction of a cysteine (C) residue in positions of the first and second CH3 domains such that a disulfide bridge between the CH3 domains can be formed.

12. A method for the preparation of the bispecific antibody according to claim 1 comprising the steps of
A) expressing in a mammalian cell nucleic acids encoding a bispecific antibody comprising
a) a full length antibody specifically binding to a first antigen and consisting of two antibody heavy chains and two antibody light chains;
b) a Fv fragment specifically binding to a second antigen comprising a VH 2 domain and a VL 2 domain, wherein the VH 2 domain and a VL 2 domains are connected via a disulfide bridge,
wherein the Fv fragment is fused
via the N-termini of the VH 2 domain and the VL 2 domain to the both C-termini of the heavy chains of the full length antibody via a first and second peptide linker, or
via the C-termini of the VH 2 domain and the VL 2 domain to the both N-termini of one heavy and one light chain of the full length antibody via a first and second peptide linker,

and wherein
one of the linkers comprises a protease cleavage site cleavable by furin, and the other linker does not comprise a protease cleavage site;
B) cleaving the linker comprising the protease cleavage site; and
C) recovering said antibody from said cell or a cell culture supernatant.

13. A method for the preparation of the trivalent, bispecific antibody according to claim 2 comprising the steps of
A) expressing in a mammalian cell nucleic acids encoding a bispecific antibody comprising
a) a full length antibody specifically binding to a first antigen and consisting of two antibody heavy chains and two antibody light chains;
b) a Fv fragment specifically binding to a second antigen comprising a VH 2 domain and a VL 2 domain, wherein the VH 2 and VL 2 domains are connected via a disulfide bridge,
wherein the Fv fragment is fused
via the N-termini of the VH 2 domain and the VL 2 domain to the both C-termini of the heavy chains of the full length antibody via a first and second peptide linker, or
via the C-termini of the VH 2 domain and the VL 2 domain to the both N-termini of the heavy chains of the full length antibody via a first and second peptide linker, and wherein
one of the linkers comprises a protease cleavage site cleavable by Prescission protease, and the other linker does not comprise a protease cleavage site;

B) cleaving the linker comprising the protease cleave site; and
C) recovering said antibody from said cell or a cell culture supernatant.

14. The method according to claim 12 , wherein the protease cleavage site cleavable by furin is SEQ ID NO:13 or SEQ ID NO:14.

15. The method according to claim 13 , wherein the protease cleavage site cleavable by Prescission protease is SEQ ID NO:15.

16. The method according to claim 12 , wherein the mammalian cell is a CHO cell, NS0 cell, SP2/0 cell, HEK293 cell, COS cell or PER.C6 cell.

17. A pharmaceutical composition comprising the bispecific antibody according to claim 1 .

18. The method according to claim 12 , wherein the VH 2 domain and the VL 2 domain of the Fv fragment are connected via a disulfide bridge which is introduced between the following positions:
i) VH 2 domain position 44 and VL 2 domain position 100,
ii) VH 2 domain position 105 and VL 2 domain position 43, or
iii) VH 2 domain position 101 and VL 2 domain position 100,
wherein the numbering is according to Kabat.

19. The method according to claim 13 , wherein the VH 2 domain and the VL 2 domain of the Fv fragment are connected via a disulfide bridge which is

Assignees

• Hoffmann La Roche
• Hoffman-La Roche Inc

Inventors

• Brinkmann Ulrich
• Haas Alexander
• Metz Silke
• Schanzer Juergen Michael

Classifications

• C07K2319/00

  Fusion polypeptide · CPC title

• C07K16/2863

  against receptors for growth factors, growth regulators · CPC title

• C07K2317/64

  comprising a combination of variable region and constant region components · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title

• C07K16/00

  Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title